42
Participants
Start Date
January 24, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Bupivacaine Hydrochloride
20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast
Liposomal Bupivacaine
20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast
Mayo Clinic Minnesota, Rochester
Lead Sponsor
Mayo Clinic
OTHER